SuperworthVor Biopharma EPS VOR
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$42.54
- Latest quarter, Q2 FY26
- −$1.16
- Fiscal year 2025
- −$292.72
Vor Biopharma's earnings per share was −$42.54 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.16.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$292.72 | n/a |
| FY2024 | −$34.02 | n/a |
| FY2023 | −$35.20 | n/a |
| FY2022 | −$47.00 | n/a |
| FY2021 | −$43.20 | n/a |
| FY2020 | −$4644.80 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.16 | n/a | −$42.54 | |
| Q1 FY26 | −$5.11 | n/a | −$292.62 | |
| Q4 FY25 | $85.36 | n/a | −$292.72 | |
| Q3 FY25 | −$121.63 | n/a | −$386.85 | |
| Q2 FY25 | −$251.24 | n/a | −$273.27 | |
| Q1 FY25 | −$5.21 | n/a | −$30.23 | |
| Q4 FY24 | −$8.77 | n/a | −$34.02 | |
| Q3 FY24 | −$8.05 | n/a | −$33.05 | |
| Q2 FY24 | −$8.20 | n/a | −$34.80 | |
| Q1 FY24 | −$9.00 | n/a | −$35.60 | |
| Q4 FY23 | −$7.80 | n/a | −$35.20 | |
| Q3 FY23 | −$9.80 | n/a | −$38.00 |
Against its peers
Companies in Biotechnology nearest Vor Biopharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| VORVor Biopharma | −$42.54 | |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| Peer median | $0.70 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vor Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.